- New Lewatit ion exchange resins and adsorbers for separation, purification, and chromatography of biomolecules
- Specific solutions for the pharmaceutical and bioprocessing industries
- Opening new market access
According to the company’s website press release on April 25, 2023, specialty chemicals company LANXESS has grouped together 16 new ion exchange resins and absorbents for the pharmaceutical and bioprocessing industries under its trusted umbrella brand Lewatit. They are used in various pharmaceutical and bioprocessing applications to separate and purify biomolecules. Applications of these end products range from food and animal feeds to active pharmaceutical ingredients (APIs) that are used in medicinal products.
“Typically, our products support the separation of biomolecules from complex biomass mixtures and play a key role in their further purification or stabilization,” explained Dr. Jenny Boettger, Technical Marketing Manager in the Liquid Purification Technologies (LPT) business unit at LANXESS. “As one of the leading manufacturers of ion exchange resins, we are hoping that this innovative product range will attract new customers from the pharmaceutical and bioprocessing industries and further strengthen our market position,” added the chemist.
New resins for downstream processes
The production of biomolecules derived from natural extracts and biological fermentation processes is strongly supported by a wide range of Lewatit ion exchange and adsorber resins. This resin technology opens up a variety of separation and purification options for all kinds of operation scales. The new types are specifically designed to be used in downstream processing for production of various biomolecules, including products from animal- and plant-sourced natural extracts. All resins are based on hydrophobic (polystyrene-divinylbenzene) or medium hydrophilic (polyacrylic) polymers. They were specifically developed to meet the high demands in industries such as biotechnology, pharmaceuticals, biopharmaceuticals, nutraceuticals, and food production in order to detoxify, convert, decolorize, or demineralize the respective molecules more easily.
Through ion exchange or adsorption processes, biomolecules such as peptides, antibiotics, vitamins, amino acids, and polysaccharides can be separated and purified more effectively. All these biomolecules are indispensable in today’s world. Antibiotics are essential for the treatment of bacterial infectious diseases. The intake of vitamins and numerous amino acids and proteins supports vital functions of the body. Diverse polysaccharides are found in part in everyday use. In the form of heparin and structure-like polysaccharides, for example, they are used to prevent venous thrombosis. In cosmetics, hyaluronic acid acts as a humectant due to its high water-binding capacity.
Outstanding features
Benefits of Lewatit include good chemical and mechanical bead stabilities, excellent kinetics and selectivity’s, high capacities, and good economics due to lean design and high performance. and come with a certificate and statement.
LANXESS’s biopharmaceutical-quality ion exchange resins and adsorbents are halal, kosher, non-GMO, and come with certificates and statements including information about allergens, heavy metals and food regulations.
Detailed information, including technical product data sheets and certificates, can be found online at https://lanxess.com/en/Products-and-Solutions/Brands/Lewatit.
LANXESS is a leading specialty chemicals company with sales of EUR 8.1 billion in 2022. The company currently has about 13,100 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives and consumer protection products. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.
Forward-Looking Statements
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.
